Skip to main content
OpenTrials
Completed

NCT Number: NCT02079350

Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation

Although the negative impacts of colloid solutions with high molecular weight on renal functions, combination of lower molecular weight colloid varieties with crystalloid solutions and its use during intraoperative period have been subject to current research. Since the first liver transplantation, pre-or post-transplantation renal problems are still among the main causes of mortality and morbidity. The aim of the study was to evaluate the effects of fluid replacement solutions used intraoperatively on renal functions in elective living-donor liver transplantation.This study was approved by the Ethics Committee of Hospital and all patients were informed and gave written consent. Participants were patients scheduled for elective living-donor liver transplantation. Patients with normal renal function were randomly allocated to infusion with 6% HES 130/0.4 (HES Group) and 4% Gelofusine (GEL Group). Blood samples were obtained before induction of anesthesia (baseline), at the end of the operation, and postoperative days 1 and 4. Different eGFR formulas using creatinine (MDRD, CKD-EPI, and Cockraud Gault) were used to calculate estimated glomerular filtration rates.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Turkey Yuksek Ihtisas Education and Research Hospital, Anesthesiology Clinic

Ankara, 06550, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Normal kidney function

Exclusion criteria

  • anormal kidney function
  • cadaveric transplantation
  • emergency operation
  • patients less than 18 years old

Treatment and study plan

%6 HES and %4 Gelofusine

Drug

Primary outcomes

  1. renal dysfunction

    Time frame: 1 month

Secondary outcomes

  1. mortality

    Time frame: 1 month

Sponsors and collaborators

Lead sponsor

Turkiye Yuksek Ihtisas Education and Research Hospital

Other Gov

Registry information

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Mar 5, 2014
Registry last updated
Mar 5, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.